Drug Type Small molecule drug |
Synonyms HEMAY 022, Hemay-022 |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Tyrosine kinase inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC32H31ClN6O4 |
InChIKeyZGYIXVSQHOKQRZ-COIATFDQSA-N |
CAS Registry1351941-69-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Phase 3 | CN | 19 Jan 2022 | |
Estrogen receptor positive breast cancer | Phase 3 | CN | 14 Jan 2022 | |
Estrogen receptor positive breast cancer | Phase 3 | CN | 14 Jan 2022 | |
HER2 Positive Breast Cancer | Phase 3 | CN | 14 Jan 2022 | |
HER2 Positive Breast Cancer | Phase 3 | CN | 14 Jan 2022 | |
Advanced breast cancer | Phase 3 | CN | 08 Jan 2022 | |
ER-positive/HER2-positive Breast Cancer | Phase 3 | CN | 08 Jan 2022 | |
Advanced HER2-Positive Breast Carcinoma | Phase 1 | CN | 14 Oct 2015 |
Phase 1 | Advanced HER2-Positive Breast Carcinoma HER2-positive | 28 | rhhyoishsi(iwacfgcwns) = pdpeuwddek efuhnjwvxg (dbfybbrmfu ) View more | Positive | 01 Jan 2024 | ||
nzoqytckvx(nyqqquvizc) = cxgrhdmbmf lgigdthuon (fevsbhlgrs ) View more | |||||||
Phase 1 | Metastatic human epidermal growth factor 2 positive carcinoma of breast estrogen receptor-positive | HER2+ | 55 | Sacibertinib plus endocrine therapy | kmkfnfpszk(uxqwuoxazk) = 9.1% ykxqojctxm (ntopuhjmhq ) View more | Positive | 05 Dec 2023 | |
Phase 1 | Metastatic human epidermal growth factor 2 positive carcinoma of breast estrogen receptor-positive | HER2-positive | 55 | Sacibertinib (Hemay022) plus endocrine therapy | klcwjtxyzg(ubwzojlhap) = naqilcofkh jbbpnoqjlt (xoxbpvshze, 5.5 - 11.0) | Positive | 05 Dec 2023 |